<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133366</url>
  </required_header>
  <id_info>
    <org_study_id>MIPO2900509</org_study_id>
    <nct_id>NCT01133366</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin</brief_title>
  <official_title>A Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of Mipomersen (200 mg SC) on Single-Dose Warfarin (25 mg) Pharmacodynamics and Pharmacokinetics in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how blood clotting and thinning time is effected when&#xD;
      a single dose of warfarin is given alone and when a single dose of warfarin is given with&#xD;
      mipomersen; to assess the blood levels of a single dose of warfarin, a single dose of&#xD;
      mipomersen, and a single dose of warfarin when given with mipomersen; and to assess the&#xD;
      safety of mipomersen when given with or without warfarin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, open-label, single-sequence, 2-period, crossover study to determine&#xD;
      the effect of multiple doses of mipomersen (200 mg SC given every other day for a total of 4&#xD;
      doses) on the PD and PK of warfarin and to evaluate the PK of mipomersen when administered&#xD;
      alone and in combination with warfarin. Subjects will be admitted to the clinic on Day -1&#xD;
      until discharge from the clinic on Day 18 and return for outpatient visits on Days 19, 20,&#xD;
      and 78. All subjects will receive a single 25-mg oral dose of warfarin given alone on Day 1&#xD;
      (designated the reference treatment). All subjects will then receive 200-mg SC doses of&#xD;
      mipomersen given every other day on Days 8, 10, 12, and 14 (total of 800 mg mipomersen) with&#xD;
      a single 25-mg oral dose of warfarin also given on Day 14 (combination designated the test&#xD;
      treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the effect curve (AUC), for INR (international normalized ratio), PT (prothrombin time), and aPTT (activated partial thromboplastin time)</measure>
    <time_frame>Serial sampling up to 144 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Value (MAX) for INR, PT and aPTT</measure>
    <time_frame>Serial sampling up to 144 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximal effect (Tmax) for INR, PT, and aPTT</measure>
    <time_frame>Serial sampling up to 144 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Warfarin Plasma Pharmacokinetic parameters (AUC 0-t, AUC 0-inf, Maximum Concentration (Cmax))</measure>
    <time_frame>Serial PK sampling up to 144 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mipomersen Plasma Pharmacokinetic parameters (AUC0-t, AUC0-inf, Cmax)</measure>
    <time_frame>Serial PK sampling up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>Through Day 78</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>warfarin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin with mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin sodium</intervention_name>
    <description>25 mg of warfarin oral (single dose)</description>
    <arm_group_label>warfarin alone</arm_group_label>
    <other_name>Coumadin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen sodium; warfarin sodium</intervention_name>
    <description>200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose</description>
    <arm_group_label>warfarin with mipomersen</arm_group_label>
    <other_name>Coumadin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent before any study-related procedure is performed.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive.&#xD;
&#xD;
          -  No clinically significant abnormalities based on medical history, laboratory&#xD;
             assessments, vital sign, 12-lead electrocardiogram (ECG) results, and physical&#xD;
             examination.&#xD;
&#xD;
          -  Subjects willing and able to follow a prescribed diet.&#xD;
&#xD;
          -  Subjects have not consumed nicotine or nicotine-containing products for at least 6&#xD;
             months before Screening.&#xD;
&#xD;
          -  Subjects are nonpregnant and nonlactating, surgically sterile, postmenopausal,&#xD;
             abstinent, or the subject or partner is willing to use a reliable method of&#xD;
             contraception during the study and for 5 months after mipomersen dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor metabolizer of warfarin as determined by CYP2C9 genotype testing.&#xD;
&#xD;
          -  Clinically significant PT, aPTT, INR, protein C, protein S, or platelet count results&#xD;
             or hematuria.&#xD;
&#xD;
          -  Abnormal prolongation of skin bleeding time or a personal or family history of&#xD;
             coagulation or bleeding disorders, vascular malformations including aneurysms, or&#xD;
             venous thromboembolism.&#xD;
&#xD;
          -  Active or recurring clinically significant cardiovascular, pulmonary, renal,&#xD;
             endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic,&#xD;
             gastrointestinal, or metabolic disease.&#xD;
&#xD;
          -  Active malignancy of any type other than nonmelanomatous skin malignancies.&#xD;
&#xD;
          -  Use of any prescribed or over-the-counter concomitant medications within 14 days&#xD;
             before the first dose of investigational product without approval of the Investigator&#xD;
             and Sponsor.&#xD;
&#xD;
          -  Positive test result for drugs of abuse, alcohol, or cotinine or history of alcohol&#xD;
             abuse or drug addiction.&#xD;
&#xD;
          -  Positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or&#xD;
             HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ISIS301012</keyword>
  <keyword>antisense</keyword>
  <keyword>ApoB (Apolipoprotein B)</keyword>
  <keyword>LDL (low density lipoprotein)</keyword>
  <keyword>mipomersen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

